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Interleukin-6 (IL-6) promotes growth and tumorigenicity of Epstein-Barr virus (EBV)-immor- 
talized B cells, and is abnormally elevated in the serum of solid organ transplant recipients who 
develop EBV-positive posttransplant lymphoproliferative disease  (PTLD),  but not in control 
transplant recipients. Endothelial cells derived from PTLD lesions were found to secrete spon- 
taneously high levels of IL-6 in vitro for up to 4 mo. We examined possible mechanisms for 
sustained IL-6 production by endothelial cells. Here, we show that EBV can infect endothelial 
cells  in vitro.  After 3-4  wk incubation  with lethally irradiated EBV-positive, but not EBV- 
negative cell lines, a proportion of human umbilical cord-derived endothelial cells (HUVECs) 
expressed in  situ  the  EBV-encoded small 1LNAs  (EBER).  Southern  blot analysis after poly- 
merase chain reaction showed EBV DNA in HUVEC that had been incubated with lethally ir- 
radiated EBV-positive ceils, but not in the controls. Exposure of HUVECs to lethally irradiated 
EBV-positive but not EBV-negative cell lines induced IL-6 production that was sustained for 
up to 120 d of culture. These studies identify endothelial cells as targets for EBV infection and 
raise the possibility that this infection may be important in the life cycle and pathology of EBV. 
E 
BV  is  a  ubiquitous  herpesvirus  that  has  developed  a 
successful  strategy for infection, persistence, and spread- 
ing  in  humans  (1).  More  than  90%  of the  population  is 
chronically  infected  with  EBV,  almost  always  without 
symptoms. The key to the successful penetration of EBV in 
humans is infection and intermittent replication in the epi- 
thelium lining the oropharynx, events that ensure spread to 
new host, and establishment of lifelong latency, probably in 
the B cells (2). 
Yet EBV infection is occasionally associated with disease 
(2).  Lymphoproliferative disorders involving EBV-infected 
B  cells arise frequently in the context of severe congenital 
or acquired immunodeficiency states (2).  As many as 30% 
of solid organ transplant recipients may develop EBV-posi- 
rive posttransplant lymphoproliferative disease (PTLD) 1 (3). 
The  association  of EBV-positive lymphoproliferative dis- 
ease with severe immunodeficiency, combined with labo- 
ratory evidence supporting the existence of a variety of im- 
mune effector mechanisms potentially involved in  control 
1Abbreviations used in this paper: EBE1K, Epstein-Barr virus-encoded small 
1KNAs; HUVEC, human umbilical vein endothelial cells; LCL, lyrnpho- 
blastoid cell lines; PTLD, posttransplant  lymphoproliferative  disease. 
of EBV infections support the notion that immune surveil- 
lance  is  critical  to  limiting  the  proliferation  potential  of 
EBV-infected  B  cells  (2).  But  other  contributing  factors 
may also be required for EBV to cause lymphoproliferative 
disease. 
Recently,  IL-6 was  found  to  increase  the  tumorigenic 
potential ofEBV-immortalized B  cells in athymic mice (4, 
5)  and  to  serve as  a growth factor for EBV-immortalized 
cells in vitro (6). IL-6 levels were also found to be elevated 
in serum or plasma of most solid organ transplant recipients 
with PTLD, but not in those with uncomplicated courses 
posttransplant,  raising the possibility that  IL-6 may play a 
role in the pathogenesis of PTLD  (7).  When incubated in 
vitro after separation into  single  cells,  PTLD  tissues  were 
found to secrete high levels of IL-6 for up to 4 mo in cul- 
ture  (7).  Cell  separation experiments identified  the  endo- 
thelial cells as the principal source of IL-6 within PTLD tis- 
sue cultures. 
The present study was undertaken to explore the mecha- 
nisms responsible for sustained IL-6 secretion by endothe- 
lial  cells  within  PTLD  lesions,  and  ultimately address  the 
role of IL-6 in the pathogenesis of PTLD. We document 
here that primary endothelial ceils are infectable with EBV 
in vitro and can produce high levels oflL-6 for up to 4 mo. 
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Cells,  Cell Lines and  Reagents.  Primary  cultures  of human 
umbilical vein  endothelial  cells  (HUVEC),  obtained from  the 
American  Type  Culture  Collection  (ATCC,  Rockville,  MD) 
were  grown in RPMI  1640 medium (GIBCO BRL,  Gaithers- 
burg, MD),  15% heat-inactivated  fetal bovine serum (FBS;  Inter- 
gen Co., Purchase, NY), 20 U/ml porcine preservative-free hep- 
arin  (Squibb-Marsam,  Inc.,  Cherry  Hill,  NJ),  and  100  Ixg/ml 
endothelial cell growth supplement (Calbiochem-Novabiochem 
Corp., La Jolla, CA). HUVEC stained positive (95-100% positiv- 
ity) for von Willebrand factor and for CD31,  as determined by 
indirect immunofluorescence using mouse mAbs to von Wille- 
brand factor  (Boehringer Mannheim Biochemicals, Indianapolis, 
IN) or to PECAM-1 (CD-31) (lq, & D  Systems, Inc., Minneapo- 
lis, MN) followed by an affinity-purified, fluorescein-labeled goat 
anti-mouse reagent  (Becton Dickinson Immunocytometry Sys- 
tems,  San Jose,  CA).  All 12  lymphoblastoid cell lines (VDS-O, 
DH, 3/22, To, Mary, RY, Rb, Rob, cb #2, TB, AVM, and IB4) 
were  obtained by  either  spontaneous  outgrowth  of peripheral 
blood  from  EBV-seropositive  individuals or  by  infection of B 
cells with the supernatant of the EBV producer marmoset cell line 
B95-8. The six EBV-negative Burkitt's lymphoma cell lines (BL- 
30,  BL-41,  ST48G,  Ramos, JD38,  and  CA46)  and  the  seven 
EBV-positive  Burkitt's  lymphoma  cell  lines  (Ag876,  Akata, 
P3HR-1, BL-30-B95, BL-41-B95, BL-41-P3HR-1), and B95-8 
were kind gifts  from Dr.  I.  T. Magrath  (National Cancer Insti- 
tute,  National  Institutes  of Health,  Bethesda,  MD).  All B  cell 
lines were  maintained in RPMI  1640  medium  (GIBCO BRL) 
supplemented with 10% heat-inactivated FBS (Intergen Co.), 2 
mM  t-glutamine  (GIBCO  BRL),  and  5  txg/ml  gentamicin 
(Sigma Chemical Co., St.  Louis, MO). All cell lines were myco- 
plasma free. Cells were irradiated in a 137Cs "/irradiator at 1 Gy/ 
min for  12  min (15,000  rad).  Human rTNF-cl was  a  gift from 
Genentech, Inc. (South San Francisco, CA); human rIL-6 was a 
gift from Sandoz Pharmaceutical (Basel, Switzerland); human riL- 
l0  was  a  gift from K.  Moore  (DNAX Research  Institute, Palo 
Alto, CA); LPS from Escherichia coli 0127:B8 was purchased from 
Sigma;  and  a  neutralizing purified  goat  antiserum  to  human 
TNF-ci was purchased from P, & D  Systems. At a concentration 
of 1 Ixg/ml, this antiserum neutralized >90% of the biological ac- 
tivity due to 50 ng/ml human rTNF-o~ (Genentech). 
Assays for IL-6,  TNF,  IFN-o6  IL-4,  IL-1~8, and IL-IO.  The 
murine hybridoma cell line B9 (a gift from Dr. R.. Nordan, Cen- 
ter for Biologics Evaluation and Research,  Bethesda,  MD)  was 
used in a standard assay for IL-6 bioactivity. 1 U  of IL-6 bioactiv- 
ity in this assay is defined as the  activity inducing half-maximal 
proliferation orB9 cells. An IL-6 concentration of i  U/ml corre- 
sponds to "~  pg ofE. coli-derived human IL-6 used throughout 
as a laboratory standard (a gift from Sandoz Pharmaceuticals). The 
fibroblast murine cell line L921  (a gift from Dr. T. Gerrard, Cen- 
ter for Biologics Evaluation and Research) was used in a standard 
assay for TNF bioactivity. 1 U  of TNF bioactivity in this assay is 
defined as the  activity inducing one-half maximal lysis  of L921 
targets.  A TNF concentration of 1 U/ml corresponds to ~100 pg 
of a human rTNF-c~ preparation (a gift from  Genentech, Inc.). 
Human IL-4 was measured in a biological assay based on its ca- 
pacity to induce CD23 expression on the Burkitt's lymphoma cell 
line, Ramos,  as  described  (8).  IL-4  concentrations were  deter- 
mined by comparison with a laboratory standard IL-4 preparation 
(Immunex Co.,  Seattle,  WA).  The  sensitivity of this  assay was 
~50 pg/ml. IFN-y levels were determined by ELISA, essentially 
as described  (8).  IFN-',/ activity was  determined by comparison 
with a standard IFN-~ preparation (Genentech, Inc.). The sensi- 
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tivity of this assay was '~10 pg/ml. IL-II3 was measured by a stan- 
dard ELISA (R &  D  Systems) by a comparison with a standard 
IL-I[~ preparation;  the  sensitivity of this assay was ~15  pg/ml. 
Human  and/or  viral  IL-10  was  measured by  a  specific  ELISA 
(Biosource International, Camarillo, CA). This ELISA uses a mu- 
fine anti-IL-10 (human and viral) mAb (IgG1  kappa clone B-S10) 
to coat the microwells, as well as a biotinylated rabbit anti-IL-10 
(human and viral) polyclonal antibody to  capture bound IL-10. 
Recombinant (E. coli-derived)  purified human IL-10 (Biosource 
International) was used as the standard. The lowest limit of sensi- 
tivity of the  assay was determined to  correspond to  11.7  pg/ml 
purified human IL-10 standard and 3.1  ￿  10 -3 U/ml viral IL-10 
(supernatant of COS  cells  transiently transfected with the  EBV 
BCR.F-1  (viral IL-10) gene, a gift from K. Moore, DNAX Re- 
search Institute). 1 U  of viral IL-10 is defined as the amount in- 
ducing half-maximal inhibition of IFN-'y production in mouse T 
cell clones (9). 
In Situ EBV Hybridization.  The procedure was performed es- 
sentially as described (10). Modification of the technique included 
a  10%  formalin fixation to  permit  the  use  of culture  chamber 
slides (Nunc, Inc., Naperville, IL) from which the upper structure 
had been removed.  The  cell-adherent slides  were  rehydrated in 
serial graded ethanol washes (70% and 50%) and subjected to pro- 
nase E  (10  Ftg/ml; Sigma)  digestion for  7  min at  37~  Slides 
were  then exposed to a sense and antisense probe  to the EBV- 
encoded small RNA EBER1  in a 50% formamide buffer for hy- 
bridization in a volume sufficient to fully cover the slide. Slides 
were covered with parafilm during the 2-h hybridization period 
at  55~  Hybridization was  followed  by  a  series  of stringent 
washes at room temperature with 2￿  SSPE  (NaCl,  Nail  2 PO4, 
EDTA solution)/0.1% SDS for 5 min, at 55~  with 0.1% SSPE/ 
0.1% SDS for 5 min, at room temperature with 2￿  SSPE for  1 
min, and then incubated for 1 h at room temperature with an al- 
kaline phosphatase-conjugated goat antibody to digoxigenin (Ge- 
nius 3  kit; Boehringer Mannheim) diluted 1:500 into  150  mM 
NaC1/100  mM  Tris solution containing 1%  goat  serum.  Slides 
were washed in 150 mM NaC1/100 mM Tris for 5 min, and in 
100 mM NaC1/50 mM MgCl  2 for 5 min, before development in 
a  5-bromo-4  chloro-3-indolyl phosphatase  (NBT)-based  color 
reaction. Slides were counterstained with eosin, dehydrated in se- 
rial  graded  ethanol washes  and  xylene,  and  mounted.  For  the 
preparation  of the  probes,  plasmids  with  the  EBERI  coding 
sequences and T7 R.NA polymerase promoters appropriately po- 
sitioned to  produce  sense  or antisense transcripts in vitro were 
provided by Dr. R. Ambinder (Johns Hopkins University, Balti- 
more, MD). Plasmids were linearized and transcribed in vitro for 
2 h at 37~  in the presence ofdigoxigenin-UTP in the appropri- 
ate transcription buffer (Genious 3  kit; Boehringer Mannheim). 
After treatment with DNAse  I  at  37~  for  15  min, the  probes 
were phenol-chloroform extracted and ethanol precipitated. Be- 
fore use, the activity of the probes was determined using a refer- 
ence standard (Genius 3 kit; Boehringer Mannheim). 
PCR and Southern Blotting.  To detect EBV DNA, we used a 
PCR  strategy based on that  of Riddler et  al.  (11).  Aliquots of 
DNA were extracted from 105 cells or from pellets derived from 
centrifugation of culture  supernatants and were  subjected  to  a 
PCR  protocol  designed to  amplify a  269-bp  segment within a 
highly conserved single-copy region of EBNA 1.  Amplifications 
were carried out in 100 txl containing 50 mM KC1,  10 mM Tris- 
HCl pH 9.0,  0.1% Triton X-100,  1.5 mM MgCl2, 200 mM of 
each dNTP,  1 I~M  of each primer (GTCATCATCATCCGG- 
GTCTC and TTCGGGTTGGAACCTCCTTG), and 2.5 U  of 
Taq DNA polymerase  (Promega  Biotech  Corp.,  Madison, WI) 
Endothelial Cells for 35 cycles of 1 min 95~  2 rain 63~  and 1 min 73~  The 
amplification  products were detected by Southern blotting.  The 
probe was a 215-bp segment of DNA internal  to the above prim- 
ers and was generated by PCR amplification  from a plasmid con- 
taining the BamI-II K fragment of the EBV genome ofB95.8 (11) 
using the primers  CCTCCAGGTAGAAGGCCATT and AC- 
CACGATGCTTTCCAAACC. The membrane was exposed to 
XAR film  (Eastman  Kodak Co.,  Rochester,  NY)  overnight at 
-70~  with an intensifying  screen. 
Cord Blood Immortalization.  HUVEC supematants were tested 
for the presence of infectious EBV by a cord blood immortaliza- 
tion assay. Cord blood mononuclear cells obtained from heparin- 
ized  cord  blood  were  seeded  in  flat-bottom  microtiter  wells 
(Costar Corp., Cambridge, MA) at 2 X 105 cells in 0.1 rnl culture 
medium  (R.PMI  1640  [GIBCO BRL] supplemented  with  10% 
heat-inactivated  FCS [Intergen Co.], 2 mM L-glutamine  [GIBCO 
BRL] and 5 p~g/ml gentamicin [Sigma Chemical Co.]). Culture 
medium, supernatant of the B95-8 cell line,  or test supernatants 
were added (0.1-ml aliquots) in triplicate  to cord blood mononu- 
clear  cells, and the cultures  were incubated for 3-4 wk. A  mi- 
croculture  was  considered  morphologically immortalized when 
large  single  cells and  clumps  of large  cells were  recognized on 
phase-contrast  microscopy.  Selected  cultures  with  microscopic 
evidence of outgrowth were  harvested  along with  control cul- 
tures  and the cells were washed;  DNA was  extracted from cell 
pellets and subjected to PCR amplification  of a 269-bp segment 
within  EBNA1,  followed  by  Southern  blotting  as  described 
above.  A  cord  blood  culture  was  considered  immortalized  by 
EBV if it appeared morphologically immortalized and contained 
EBNA1 sequences. 
Results 
IL-6 Production by Endothelial Cells Exposed to EBVoimmor- 
talized  B  Cells.  Previous  experiments  demonstrated  that 
endothelial  cells  derived  from lymphoproliferative  lesions 
of patients with PTLD produce high levels of IL-6 in cul- 
ture for periods of weeks  (7).  With the goal of establishing 
the mechanism of IL-6 induction in these  cells,  we tested 
whether  normal human endothelial  cells  are stimulated  to 
secrete  IL-6  by  EBV-immortalized  cells.  To  this  end, 
HUVECs were cultured in 24-well plates until confluency. 
Subsequently,  the  effects  of four  EBV-immortalized  cell 
lines were tested by adding 106 irradiated  (15,000 rad) cells 
to each HUVEC-containing well or to empty wells.  Cul- 
tures were then continued with periodic (once or twice per 
week)  exchange  of one-half (1  ml)  culture  medium  with 
fresh medium. As shown in Fig. 1, HUVEC culture super- 
natants  incubated alone contained at most 218  IL-6 U/ml 
during a 66-d culture period.  In contrast,  culture superna- 
tants of HUVEC incubated in parallel with irradiated EBV- 
immortalized  cells  from four separate  cell  lines  contained 
much higher IL-6 levels,  reaching 4,790 and 28,840 U/nil 
during the same incubation period. Because culture super- 
natants  of the  heavily  irradiated  EBV-immortalized  cell 
lines  incubated  alone  contained  at  most  269  IL-6 U/ml, 
and because the cell viability of  EBV-immortalized cells  11 d 
after irradiation was <2% both when cultured alone and on 
HUVEC  monolayers,  we  concluded  that  HUVECs  were 
the likely source of IL-6 in the cultures. 
Regular  inspection  of HUVEC  cultures  by phase-con- 
trast microscopy at intervals during incubation either alone 
or with irradiated  EBV-immortalized  cells  showed a pro- 
gressive loss of confluency in the cell monolayer, presum- 
ably  secondary  to  cell  death  and  subsequent  detachment 
from  plastic.  Initially,  HUVECs  constituted  a  homoge- 
neous population of closely opposed, large, polygonal cells 
with a centrally located nucleus and indistinct cell borders. 
By day 30 or 40 of culture, only sparse adherent cells were 
visible,  but  these  cells  maintained  the  original  aspect  of 
large, polygonal cells with central/y located nucleus. 
To  test  further  IL-6 production  in  this  setting,  we  re- 
peated  the  study  to  include  12  lymphoblastoid  cell  lines 
(LCL)  obtained  by  either  spontaneous  or  EBV  (B95-8 
strain)-induced  immortalization;  six  EBV-negative  Bur- 
kitt's lymphoma cell lines;  six EBV-positive Burkitt's lym- 
phoma cell lines  (including three EBV-converted Burkitt's 
lymphoma cell lines BL-30[B95-8] and BL-41  [B95-8 and 
P3HR-1],  and  three  EBV-producer  cell  lines  P3HR-1, 
Ag876, and Akata); and the EBV-producer marmoset B95-8 
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Figure  1.  Levels of IL-6 in cultures of endothelial 
cells incubated  with  EBV-immortalized  cell lines. 
HUVEC were first cultured to confluency in 24-well 
plates and then incubated with  106 irradiated (15,000 
rad) EBV-immortalized cells from the cell lines DH, 
Mary, TB  and VDS-O.  Controls included HUVEC 
and irradiated B cell lines cultured alone. Cultures were 
periodically fed as needed, and supernatants were tested 
for IL-6 content at the indicated time points. 
1215  Jones et al. cell line (Fig. 2). Cell cultures were maintained for 28-112 d, 
and culture supernatants were tested for IL-6 at 3-10 d in- 
tervals throughout  the  culture  period.  We looked for the 
highest  IL-6 levels  achieved  in  the  supernatants  (Fig.  2). 
The mean highest  IL-6 level measured in supematants of 
HUVECs  cultured  alone was  118  X/:  1.2  U/ml,  a level 
significantly lower than  that measured in the supernatants 
of HUVECs cultured with irradiated LCL (4,574  ￿  1.5) 
and in the supernatants of HUVECs cultured with the irra- 
diated EBV-positive lymphoma cell lines  (1,572  ￿  1.9), 
as determined by group  comparison using Dunnett's  test. 
In contrast, the mean highest IL-6 level in supernatants of 
HUVECs  alone was not significantly different  (Dunnett's 
test) from that measured in supernatants of HUVECs cul- 
tured  with  irradiated  EBV-negative  lymphoma  cell  lines 
(184  ￿  1.2).  As expected, culture supematants of all irra- 
diated cell lines incubated in the absence of HUVEC con- 
tained  little  IL-6.  These  experiments  demonstrated  that 
HUVECs  can be induced  to  secrete  IL-6 by a variety of 
EBV-positive but not EBV-negative cell lines. 
Kinetics of IL-6 production by endothelial cells exposed 
to  LCL  or  to  EBV-producing  cell  lines  (Ag876,  B95-8, 
Akata,  and  P3HR-1)  showed  that  peak  cytokine  levels 
were achieved, on the average, on day 24  (range 9-85)  of 
culture. IL-6 levels, however, were found to be above con- 
trols (endothelial cells alone and irradiated LCL alone), on 
the average, up to day 47 (range 19-93) of culture. 
Mechanisms of IL-6 Production by Endothelial Cells Exposed 
to  EBV-infected  Cell Lines.  Previous  studies  have  shown 
that endothelial cells can be induced to produce IL-6 by a 
variety  of signals,  including  LPS,  IL-lJ3,  TNF-ot,  IL-4 
alone or with IFN-0t, and to a limited extent,  IL-10 (12- 
14).  It was unlikely that LPS was responsible for IL-6 in- 
duction  in our system because the  endotoxin level in the 
culture supernatants of four IL-6 inducing B  cell lines was 
<0.06  endotoxin U/ml,  a dose not different from that of 
medium alone.  It was also unlikely  that  IL-I~, IL-4, and 
IFN-3, were involved in our system because IL-115,  IL-4, 
and IFN-y were undetectable in the culture supernatants of 
eight of eight LCL and in four of four of the EBV-positive 
Burkitt's lymphoma lines tested (not shown) using ELISAs 
with detection limits 10-20-fold lower than the amounts of 
cytokine required for induction of IL-6 in endothelial cells. 
LCLs, however, are known to secrete TNF (15) and IL-10 
(16),  and  we  determined  that  2-d culture  supernatants  of 
eight irradiated LCL (106 cells per ml) contained a mean of 
38.8  TNF  U/ml,  and  six  of eight  had  detectable  IL-10. 
Addition of TNF-ot (1.5-50 ng/ml, corresponding to 4-135 
U/ml)  to HUVEC resulted in  the induction  of IL-6 (not 
shown). The kinetics of IL-6 production induced by TNF-0t, 
however, differed from those induced by LCL in that peak 
IL-6 levels were measured, on the average, on day 9 with 
TNF-o~ at the highest  dose  (earlier at lower doses)  versus 
day 24  with EBV-positive lines.  In  addition,  the  IL-6 re- 
sponse to TNF was undetectabte, on the average, by day 38 
(or earlier at lower doses), but continued up to day 47,  on 
the  average, with  exposure to  the  cell lines  (not shown). 
Measurements of IL-6 and TNF levels in HUVEC super- 
natants exposed to the Ag876 lines during a  126-d period 
revealed a  discordance  between  TNF,  which  was  detect- 
able only initially in the culture, and IL-6, which  was de- 
tectable throughout  (Fig.  3 A). Also, addition of a neutral- 
izing antibody to  human  TNF-oe had  minimal  effects on 
IL-6 production by LCL-exposed HUVEC after a modest 
diminution early in the culture  (Fig.  3  B).  In control cul- 
tures,  the  anti-TNF-0t  antibody  markedly  reduced  IL-6 
production induced by 10 ng/ml TNF-o~ (Fig.  3/3).  in re- 
lated experiments, we found that human rlL-10 (10 ng/ml) 
did  not  increase  IL-6  production  by  HUVECs  (not 
shown). The combined effects of TNF-ot (ng/ml) plus IL- 
l0 (10 ng/rnl) on IL-6 production by HUVECs was similar 
to that of TNF-ot (10 ng/ml) alone.  Finally, in three sepa- 
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Figure  2.  IL-6  production in endothelial cell cul- 
tures incubated with EBV-positive and EBV-negative 
B cell lines. The  culture conditions are identical to 
those described in the legend to Fig. 1; time in culture 
varied from 28 to 112 d. The results reflect the highest 
IL-6 level measured in the culture supernatants tested 
at 3-10-d intervals. 
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rate  experiments  (not  shown),  supernatants  of two  EBV- 
immortalized  ceil lines  (VDS-O  and DH),  of three  EBV- 
positive Burkitt's lymphoma cell lines  (Ag876, Akata,  and 
P3HP,.-1), and of the EBV-producer B95-8 ceil line added 
once  to  HUVEC  cultures  (1:2  dilution)  failed  to  induce 
IL-6  production  in  these  cells  during  a  20-55  d  period. 
These findings suggested that any cytokines that might be 
released by EBV-immortalized cells cannot account for IL-6 
secretion by HUVECs exposed to EBV-positive cell lines. 
Endothelial  Cells Are  Infected  by EBV  and  Replicate  h~fec- 
tious  EBV.  The  observation  that  HUVECs  exposed  to 
EBV-infected irradiated  cell lines produce higher levels of 
IL-6 than HUVECs cultured alone for a prolonged period, 
up to  125 d, raised the possibility that the endothelial  cells 
might become infected with EBV, and that EBV infection 
might promote  IL-6 secretion.  To  address  this possibility, 
HUVECs were first cultured for 3-4 wk in chamber slides 
either alone or with irradiated B  cell lines  (105 per w), and 
were then  examined for evidence of EBV infection.  After 
the  removal  of all  cells  and  cell  fragments  in  suspension, 
glass-adherent  cells  were fixed and subjected to in situ hy- 
bridization  using  probes  for  the  highly  transcribed  EBV- 
encoded small P,  NAs  (EBERs).  In situ  hybridization with 
probes in the sense orientation was used as a control. Using 
this technique,  we found that HUVECs exposed to irradi- 
ated EBV-positive lymphoblastoid cell lines (DH, VDS-O, 
R.Y, and TB)  or to the EBV-positive Burkitt's Ag876 cell 
line  expressed  EBV-specific  EBER1  mRNA.  Control 
HUVECs either cultured  alone or exposed to EBV-nega- 
tive Burkitt's  ceils  (PCA46 and JD38)  were EBV negative 
by the same assay.  In one experiment,  >50% of the adher- 
ent cells  exposed to VDS-O cells were found to be EBV- 
positive  (Fig.  4  A).  In most other  experiments,  however, 
the  level  of EBV  positivity  was  in  the  5-10%  range.  It 
should be noted, however, that in most cases the percent of 
cell positivity could not be accurately determined because a 
proportion  of the  adherent  cells  was  lost  during  fixation 
and  staining.  The  cells  staining  positive  for  EBER  were 
likely to be HUVECs and not the EBV-positive B cells be- 
cause  of their  elongated  morphology  and  adherence  to 
Figure 3.  TNF production by EBV-infected cells is 
not solely responsible for IL-6 production in cultures of 
HUVEC with EBV-infected cells. (A) Levels of IL-6 
and TNF in supernatants of endothelial cells incubated 
with the EBV-positive Ag876 cell line. The  culture 
conditions are identical to those described in the legend 
to Fig. 1. The results reflect IL-6 and TNF levels mea- 
sured in supernatants obtained at the indicated culture 
time points. (B) IL-6 production by endothelial cells 
exposed to TNF-~ alone, TNF-ot plus anti-TNF-ct- 
neutralizing antibody, irradiated EBV-positive VDS-O 
cells alone, or VDS-O cells plus anti-TNF-~-neutral- 
izing antibody. Confluent HUVEC cultures received 
either TNF-cx (10 ng/nfl) alone or with a neutralizing 
antibody to TNF-~ (1  ~g/ml),  or irradiated (15,000 
rad) VDS-O cells (10  6 per well) alone or with a neu- 
tralizing antibody to TNF-ct (1 p.g/nil). The results re- 
flect IL-6 levels in the culture supematants at various 
time points. 
glass.  Indeed, control chamber slides containing the irradi- 
ated EBV-positive ceils alone (no endothelial  cells)  had no 
visible  glass-adherent  cells.  These  findings  suggested  that 
upon  culture  with  irradiated  EBV-positive  cell  lines, 
HUVECs become infected with EBV. 
To confirm this finding,  we looked for the presence  of 
the EBV-DNA in HUVEC through PCR. amplification of 
the  EBNA I  gene  followed  by  Southern  blotting  of the 
PCR products. Monolayers of HUVECs were cultured ei- 
ther alone  or with  irradiated  EBV-infected  cells  from the 
lymphoblastoid cell line VDS-O (106/ml). Irradiated VDS-O 
cells were also cultured alone (2 ￿  106/ml). A~er 9, 16, 24, 
and 30 d incubation,  10  s live adherent ceils were obtained 
from HUVEC  cultures.  At the  same  time  points,  nonad- 
herent  cells  and  cell  fragments  were  recovered from cul- 
tures  of HUVEC  incubated  with  irradiated  VDS-O  cells, 
and of irradiated VDS-O cells  cultured alone. Because the 
viabilities  of the  nonadherent  cell  populations  recovered 
from cultures  of irradiated  VDS-O cells  alone were 9-12, 
0-1, 0, and 0% after 9,  14, 24, and 30 d incubation,  but it 
was possible that EBV DNA might still be present, we sub- 
jected to PCP,. amplification all  nonadherent  cells  and cell 
fragments  recovered  from  centrifugation  of 3-ml  culture 
supernatants  from the  cocultures  (HUVEC  plus  irradiated 
VDS-O cells)  and from cultures of irradiated VDS-O cells 
cultured alone. The results of Southern blotting after PCR 
amplification  (Fig.  5)  show  that  HUVEC  cultured  alone 
(lanes a) were negative for EBNA 1 at all time points  (days 
9,  16,  23,  and  30),  but  HUVECs  exposed  to  irradiated 
VDS-O cells  (lanes b) were positive for EBNA 1 at all time 
points.  In contrast,  the  irradiated  (15,000  rad)  EBV-posi- 
tive  VDS-O  cells  (lanes  d)  scored  positively  for EBNA1 
only at the first time point, day 9 after irradiation,  but they 
scored negatively for EBNA1  at  all  later  time  points  (16, 
23, and 30 d after irradiation).  The nonadherent cell popu- 
lation recovered from cocultures of HUVEC and irradiated 
VDS-O cells (lanes c) scored positive for EBNA 1 at all time 
points  (days  9,  16,  23,  and  30).  Because  the  irradiated 
VDS-O cells  cultured alone scored negatively for EBNA I 
on 16 d  after irradiation  and thereafter,  we concluded that 
1217  Jones et al. Figure 4.  Detection of EBEK1 transcripts in endothelial cells exposed 
to irradiated EBV-immortalized cells. In situ hybridization with digoxige- 
nin-labeled  EBEP,-specific antisense probes showing intense EBEK posi- 
tivity in cell nuclei (A). Control hybridization with EBER.-specific sense 
probes (B). Slides were counterstained with eosin. ￿ 800. 
the  EBNA I  positivity of this nonadherent cell population 
(derived  from  the  coculture  of HUVECs  plus  irradiated 
VDS-O  cells)  beyond day  9  of culture  had  resulted  from 
EBNA-positive HUVECs  that had detached from the plas- 
tic surface. 
In additional experiments,  we  examined whether EBV- 
infected HUVECs  replicate infectious EBV capable of im- 
mortalizing cord blood lymphocytes.  To this end,  aliquots 
of culture supernatants from HUVECs  incubated either in 
medium alone or with irradiated (15,000 rad) EBV-positive 
lymphoblastoid cells  (VDS-O  cell line) were  harvested on 
days 8  or 16 of culture, and 0.1  ml was transferred in tripli- 
cate to microtiter cultures containing cord blood mononu- 
clear cells  (2  ￿  10  s  in 0.1  ml culture  medium).  Superna- 
tants  of the  EBV-producer  B95-8  cell  line  and  complete 
HUVEC  culture medium served as controls. A  cord blood 
microculture  was  considered  morphologically  immortal- 
ized when both large single cells and clumps of large  cells 
were  recognized on phase-contrast microscopy.  As  shown 
in Table  1,  a  proportion  of cord  blood  mononuclear cell 
cultures developed evidence of immortalization after expo- 
sure to supernatants of HUVEC  cultured for 8 or 16 d with 
irradiated  EBV-immortalized  cells.  In  contrast,  there  was 
no evidence of immortalization in cord blood mononuclear 
cell cultures  exposed  to  supernatants of HUVEC  cultured 
Table 1.  Detection of Infectious EB V in Culture  Supernatants  of 
HUVEC 
Immortalized cultures* 
(No. of positive wells/ 
total no. of wells) 
Test samples*  Experiment 1  Experiment 2 
HUVEC medium  0/3  0/3 
P.PMI medium  0/3  0/3 
B95-8 supematant  3/3  3/3 
8-d supernatant irradiated  0/9w  ND 
VDS-O 
16-d supernatant irradiated  ND  0/6  w 
VDS-O 
8-d supernatant HUVEC  0/9  ND 
16-d supematant HUVEC  ND  0/6 
8-d supernatant HUVEC  +  10/12  u  ND 
irradiated VDS-O 
16-d supernatant HUVEC  +  ND  2/64 
irradiated VDS-O 
Figure 5.  Detection of EBV-DNA in endothelial cells cultured with 
irradiated EBV-imrnortalized cells. Confluent HUVEC cells were either 
cultured alone or with irradiated (15,000) lymphoblastoid cells (VDS-O 
line 106 cells per well). Irradiated VDS-O cells were also cultured alone. 
At the indicated  time points  (9,  16, 23,  and 30  d),  HUVEC  <ultured 
alone (a), adherent cells from cultures of HUVEC plus irradiated VDS-O 
ceils (b), nonadherent ceils from HUVEC cultures plus irradiated VDS-O 
cells (c), and irradiated VDS-O cells cultured alone (d) were harvested and 
subjected simultaneously to  PCtL  amplification of the  EBNA1  region 
with appropriate primers. The results reflect Southern  blot hybridization 
with an EBNA/-specific probe. 
* An aliquot (0.1 ml) of the indicated test samples was added to microti- 
ter wells containing freshly isolated cord blood mononuclear cells (2  ￿ 
105 in 0.l ml culture medium), and the cultures were incubated for 3-4 
wk. 
*A cord blood culture was considered immortalized if it contained large 
single cells and clumps of large cells after 3-4 wk of culture,  as deter- 
mined by phase-contrast  microscopy. 
w  pool of four (out of nine) wells and a pool of all six wells tested neg- 
ative for EBNA 1 DNA. 
13  of  10  immortalized  wells  tested  individually  were  positive  for 
EBNA 1 DNA. 
~A pool  of the  two  immortalized  wells  tested  positive  for  EBNA1 
DNA. 
ND, not done. 
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cells  irradiated  8  or  16  d  earlier and then incubated.  The 
presence  of EBV  DNA  in  morphologically immortalized 
cord blood cultures was assessed  through  PCR  amplifica- 
tion  of EBNA/-specific  sequences  followed by Southern 
blotting.  Three  individual  wells  and  a  pool of two  wells 
scored  positively for EBNA 1.  In  contrast,  pools  of wells 
containing cord blood mononuclear cells exposed to super- 
natants of EBV-immortalized cells irradiated 8 or 16 d ear- 
lier did not appear immortalized, and they tested negative 
for EBNA 1. 
Together, these findings demonstrate that HUVECs ex- 
posed to lethally irradiated EBV-immortalized cells become 
EBV-infected, and they can replicate infectious EBV. 
Discussion 
In the present studies,  we have demonstrated that  after 
incubation with lethally irradiated EBV-infected cells,  hu- 
man  umbilical  cord-derived  endothelial  cells  become in- 
fected with  EBV  and  secrete  high  levels  of IL-6 for ex- 
tended  periods  of  culture.  Although  it  is  known  that 
endothelial cells can be induced to secrete IL-6 by a variety 
of signals  (12,  14),  it has not been previously reported that 
endothelial  cells  can be infected with EBV.  The evidence 
supporting  the  assertion  that  endothelial  cells  can  be  in- 
fected with EBV derives from in situ hybridization studies 
that have detected the presence of EBERs, as well as from 
Southern analyses after PCR amplification that have dem- 
onstrated the presence of EBNA1  sequences in the endo- 
thelial  cells.  The  EBV  specificity of each  of these  assays 
strongly supports  the  notion  that  endothelial  cells  can be 
infected with EBV in vitro. 
The relationship between EBV infection and IL-6 secre- 
tion in endothelial cells was not fully elucidated here.  It is 
likely,  however,  that EBV  infection  directly or indirectly 
stimulates IL-6 production by endothelial cells  in the pre- 
sent system. It would be difficult to envision an alternative 
mechanism  by  which  endothelial  cells  might  sustain  in- 
creased IL-6 production for a period longer than  120 d in 
response  to  irradiated  cells  that  are  all  dead  7-9  d  after 
15,000  rad  irradiation.  Furthermore,  incubation  of endo- 
thelial  cells  with  a  number of EBV-negative irradiated  B 
cell lines  was not  associated with  increased  IL-6 produc- 
tion, further suggesting a link between EBV and the IL-6- 
inducing signal.  It is interesting to note that in six separate 
attempts we have failed to infect HUVECs with EBV by 
exposing them  to  culture  supernatants  of the  B95-8  and 
Ag876 cell lines that were found to contain ~103 infectious 
units  per ml  (results  not  shown).  It remains  to  be  estab- 
lished whether this resulted from insufficient virus or from 
a requirement for signals  other than the virus itself for in- 
fection of endothelial cells. 
The nature of EBV infection in endothelial cells was not 
fully elucidated  here.  Two preliminary observations were 
made,  however  (results  not  shown).  In almost all  experi- 
ments, endothelial cells exposed to EBV-immortalized cells 
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and producing high levels of IL-6 lived longer than endo- 
thelial cells  cultured in medium alone or with EBV-nega- 
tive  cell  lines.  This  suggested  that  EBV  infection  might 
provide a  survival advantage to  endothelial  cells.  Also,  in 
two experiments, we documented the presence of immor- 
talizing EBV in the culture supematant of endothelial cells 
that had been exposed to irradiated EBV-immortalized cells 
2  wk earlier,  but  not in  control  supematants  of HUVEC 
cultured  alone  or  in  supernatants  of EBV-immortalized 
cells  that had been irradiated  8  or  16  d  earlier,  indicating 
that EBV replication had occurred in the endothelial cells. 
Another  issue  that  remains  unclear  is  how  EBV  enters 
HUVECs. Endothelial  cells  of small vessels  were reported 
to stain positive for the EBV receptor molecule CD21  (17, 
18), but using immunofluorescence, we found no evidence 
for the presence of CD21  on HUVECs  (not shown). The 
presence of EBV receptors on epithelial cells and on malig- 
nant T  cells  has been difficult to document,  even though 
these cell types are EBV infectable (19-21).  The observa- 
tion that supernatants of  EBV-producing and EBV-immor- 
talized cell lines  failed to  induce  EBV infection  and  IL-6 
production  in  HUVECs  suggests  that  cell-to-cell  contact 
may render EBV infection more efficient at low virus titers. 
Future  studies  will  address  both  EBV  gene  expression  in 
endothelial cells and EBV entry. 
The observation that human endothelial cells are infect- 
able with  EBV  and  can replicate infectious EBV  in vitro 
raises  the possibility that these cells might also become in- 
fected with EBV in vivo. We have looked for EBV in the 
endothelial cells  of two biopsy specimens of PTLD tissues 
by in situ hybridization and found them to be EBV nega- 
tive.  Because  only  a  small  fraction  of  endothelial  cells 
within  PTLD lesions might be EBV-infected,  however,  a 
more extensive and rigorous search will be needed to fully 
evaluate their EBV status.  On the basis  of the in vitro re- 
sults reported here, we would predict that prolonged con- 
tact  of EBV-producing  cells  with  endothelial  cells  will 
result in EBV infection of the endothelial cells. EBV repli- 
cation is believed to occur in some PTLD lesions (22),  and 
the possibility of prolonged contact of EBV producing cells 
with endothelial cells within PTLD lesions exists.  As noted 
here,  IL-6 secretion is likely to be one of the outcomes of 
infection with EBV in vitro. Because IL-6 is known to rep- 
resent a growth factor for EBV-infected B cells (6, 23), en- 
dothelial  cell infection with EBV and  the  associated IL-6 
production may constitute a local stimulus for PTLD pro- 
gression. 
Could endothelial cells represent a site of EBV infection 
in the normal life cycle of the virus, either during primary 
or latent infection of otherwise healthy individuals? There 
is  no  direct  evidence  that  cell  types  other  than  epithelial 
cells and B cells are normally infected with EBV in vivo (1, 
2).  There are several missing or uncertain links in the life 
cycle of EBV in  this host,  however,  particularly the  rela- 
tionship  that  exists between EBV-productive infection in 
the differentiating epithelium of the oropharynx and EBV 
latency in the B cell compartment (2). We know that EBV 
is periodically replicated in the oropharynx throughout life, and although many EBV variants are generated during viral 
replication, the same EBV isolate is detected in the saliva of 
an infected individual  over a period of many years (24).  It 
was  proposed  that  endogenous  virus  must  be  fed  to  the 
oropharyngeal epithelium from a latent reservoir where the 
virus  is  protected  from  change  associated  with  extensive 
replication  (25).  But  the  only  other  known  site  of EBV 
persistence,  the  B  cells,  is  an  unlikely  source  of virus be- 
cause of the latent nature of EBV infection here (1).  Could 
endothelial cells serve such a role? 
EBV-seropositive normal individuals  harbor a small and 
relatively constant number of EBV-infected B  cells  in the 
peripheral  blood  (2,  26)  despite  EBV-specific cytotoxic T 
cell precursors that account for 1 per 103-104 circulating T 
cells  (25, 27).  How can EBV-infected B  cells  escape T  cell 
killing?  Since the  specificity of the viral-specific  cytotoxic 
cell  population  was  mapped  to  a  number  of viral  latency 
genes,  including  EBNA4,  EBNA2,  EBNA3a,  EBNA3c, 
and  LMPI  (28-33),  but  not  to  EBNA1,  it  was  proposed 
that EBV-infected B  cells in seropositive normals may ex- 
press  EBNA I  only  or mutated  viral  epitopes  selected  for 
CTL resistance  (25,  34).  But recently,  several studies  have 
documented expression of EBNA4 and other EBV latency 
genes in the  circulating B  cells  (35,  36),  suggesting that at 
least some virally infected B  cells  are targets of T  cell cyto- 
toxicity.  Could endothelial  cells  in EBV-seropositive  nor- 
mals represent a reservoir for EBV that continuously infects 
B cells,  replacing those destroyed by cytotoxic T  cells? 
In addition to B lymphocytes and epithelial cells,  T  lym- 
phocytes  from  certain  lymphoproliferative  diseases  were 
found to harbor EBV (20, 21). Reed-Sternberg and Hodg- 
kin's  cells  are known to carry EBV genomes in ,'~50% of 
Hodgkin's  lymphoma  specimens  (10,  37).  Furthermore, 
some  follicular  dendritic  cells  were  successfully  infected 
with  EBV in vitro  (38).  Recently,  smooth  muscle tumors 
in either immunosuppressed AIDS patients or recipients of 
liver transplant were found to be EBV infected (39, 40). 
Many  questions  remain  to  be  addressed,  including  the 
nature  of endothelial  cell infection with EBV,  the  pattern 
of gene  expression  by the  endothelial  cells,  and  the  rele- 
vance of in vitro endothelial cell infection with EBV to the 
in vivo situation,  both in diseased and normal individuals. 
The novel observation that  endothelial  cells  are  infectable 
by EBV, however, has the potential to clarify some critical 
issues  of EBV infection that remain unresolved. 
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